GlassScriptPhysician profile
Marty Cole
NPI 1295846681
$27,788.57
in general payments reported to CMS, 2019-2025
7 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2024: $6,480 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,540.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27,540.00 | 2024-2025 | |
| Novo Nordisk INC | $131.44 | 2019 | |
| Glaxosmithkline, LLC. | $47.84 | 2019 | |
| Lilly USA, LLC | $25.72 | 2019 | |
| Medtronic USA, INC. | $25.66 | 2019 | |
| Astellas Pharma US INC | $14.90 | 2019 | |
| Neuronetics, INC. | $3.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marty Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.